Eurofins Scientific (Euronext Paris: ERF), the European lab-testing group, closed at EUR 78.94 on October 19, 2026. A REIT-focused investor on X says Eurofins Scientific is "still cheap" because margins are rising, free cash flow should jump and the company keeps buying back stock. The next tests are the nine-month trading update on October 21, 2026 and an investor day on October 23.
This is journalism and commentary, not investment advice. We hold no position unless stated.
Key facts
- Ticker and exchange: Eurofins Scientific SE, ERF, Euronext Paris.
- Situation type: cash-flow inflection plus steady buybacks, two years after an activist short report.
- The call: long, from the X account Mr Neutral Man, first on August 20, 2026 at a EUR 70.66 basis and repeated on October 13 at EUR 77.66.
- Price: EUR 78.94 on October 19, 2026, roughly EUR 13.9 billion of market value on our math.
- Cash flow: free cash flow to the firm rose 46% to EUR 403 million in the first half of 2026.
- Buybacks: about 3.52 million shares bought in weekly reports from August 24 to October 16, 2026.
- Catalysts: nine-month trading update October 21, Europe investor day October 23, North America investor day November 11, 2026.
- Main risk: slow organic growth and lingering governance doubts from the 2024 Muddy Waters report.
Is ERF a good bet right now?
The case for Eurofins Scientific is that profits and cash are rising faster than sales. The case against is that sales growth is still well below the company's own long-term goal.
On our rough math, about 176 million shares at EUR 78.94 plus EUR 3,854 million of net debt gives an enterprise value near EUR 17.75 billion. Simply doubling first-half adjusted EBITDA of EUR 877 million puts that near 10 times. That is a shortcut, not a forecast.
Eurofins Scientific is up about 1.6% since the October 13 call and about 11.7% since the August 20 post.
Why are investors bullish on Eurofins Scientific?
- Margins are near target. The H1 2026 results show a 23.7% adjusted EBITDA margin, up from 22.4%, against a 24% goal for 2027.
- Capex is falling. Net operating capex dropped to 3.9% of revenue from 4.8%, as several expansion programs finished.
- Earnings per share grew. Basic EPS rose 29% to EUR 1.55 from EUR 1.20.
- Buybacks are large. Eurofins Scientific repurchased 3,653,476 shares at an average EUR 63.04 in the first half of 2026.
- The buyback leans in on dips. The buyback page shows 1,422,106 shares bought from September 7 to 11, 2026 at an average EUR 71.23, the biggest week since August.
Who's making this call and why?
Mr Neutral Man (@Mr_Neutral_Man) brands himself the "Howard Marks of REITs" and writes about buying real estate below private-market value. His profile links to the Hard Asset Memo Substack. On October 13, 2026 he posted that Eurofins Scientific has 23-24% EBITDA margins and recurring revenue, and that free cash flow will spike in 12 to 18 months. His summary: "Still cheap today and buying back a ton of stock."
In September he replied to a post on buybacks by Bireme Capital's Evan Tindell, writing that "Fcf should ramp next year allowing them to really buy back a truck load." Tindell's post was about buybacks in general and did not name Eurofins.
Track record. Mr Neutral Man is not yet on our scoreboard, so he has no scored record. Our own 30-day checks of his two earlier Eurofins posts both beat the S&P 500, by 9.74 and 6.66 points. That is far too short to judge. See the scoreboard.
Other voices:
- Value-Investor.net (@value_investor1), a DACH-focused value investor who disclosed a long position, wrote on results day, July 23, 2026: "Eurofins sold off despite a strong H1." The account argued the market was fixated on weak organic growth and a delayed biopharma recovery, not falling fundamentals.
Who disagrees?
The best-known bear is Muddy Waters Research. On June 24, 2024 it posted: "MW is short Eurofins Scientific bc it seems optimized for malfeasance." The report alleged that the controlling shareholder had siphoned money from the company for two decades and that the accounts could overstate profits, cash and assets.
- The market reacted hard. Reuters reported the shares fell as much as 25% on the day.
- Eurofins denied it. In its response, Eurofins Scientific called the allegations "inaccurate, irrelevant, biased and/or misleading."
- The short worked at first. In our tracking, Eurofins Scientific fell 7.89% over 180 days from the EUR 52.74 pre-report close while the S&P 500 rose 9.32%, a win for the short.
- Then it reversed. At EUR 78.94, Eurofins Scientific is about 49.7% above that pre-report close. We found no public update from Muddy Waters on whether it is still short.
The fundamental bear point is growth. Organic growth was 2.7% in the first half of 2026, against a long-term objective of 6.5% a year, and biopharma demand stayed slow.
What are the key facts to verify?
- The H1 2026 results: FCF, net debt of EUR 3,854 million and leverage of 2.2 times.
- The financial calendar for the October 21 update and investor days.
- Weekly figures on the buyback page; the current tranche runs to October 21, 2026.
- The Muddy Waters report and the company's rebuttal.
What would prove it right or wrong?
Right: organic growth picks up toward mid-single digits, cash conversion keeps rising toward the 2027 goal of above 50%, and buybacks continue after the current tranche.
Wrong: organic growth stalls near 3%, free cash flow misses, buybacks slow, or new governance or accounting questions surface.
This is journalism and commentary, not investment advice. We hold no position unless stated.